AVE 0991

Description

AVE 0991 is an orally active, non-peptide angiotensin (1-7) receptor agonist with an IC50 of 21 nM.

IC50 and target

IC50: 21 ± 35 nM (receptor Ang- (1-7))

In vitro

AVE 0991 is a non-peptide compound that evokes Ang- (1-7) -like effects on the endothelium. AVE 0991 and unlabeled Ang- (1-7) compete for high-affinity binding of -Ang- (1-7) to bovine aortic endothelial cell membranes with IC50s of 21 ± 35 and 220 ± 280 nM, respectively.

The maximum concentrations of NO and O2 release by the sodium salt AVE 0991 and Ang- (1-7) (both 10 μM) are not significantly different (NO: 295 ± 20 and 270 ± 25 nM; O2-: 18 ± 2 and 20 ± 4 nM). However, the amount of bioactive NO released is ~ 5 times higher for AVE 0991 compared to Ang- (1-7). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Live

AVE 0991 (0.58 nmol / g) produces a significant decrease in water diuresis in WT mice compared to vehicle treated animals (0.06 ± 0.03 ml vs 0.27 ± 0.05; n = 9 for each group; P <0.01). The antidiuretic effect of AVE 0991 (AVE) is associated with an increase in urine osmolality (1669 ± 231.0 mOsm / KgH2O versus 681.1 ± 165.8 mOsm / KgH2O in vehicle-treated mice; P <0 , 01).

The Mas genetic deletion nullifies the antidiuretic effect of AVE 0991 during water loading (0.37 ± 0.10 ml [n = 9] vs 0.27 ± 0.03 ml [n = 11] in mice treated with AVE 0991). As observed with C57BL / 6 mice, administration of AVE 0991 (0.58 nmol / g) in water-loaded Swiss mice also produces a significant decrease in urinary volume compared to vehicle-treated animals (0.13 ± 0.05 mL [n = 16] versus 0.51 ± 0.04 mL [n = 40]; P <0.01).

One week of treatment with AVE-0991 produces a significant decrease in perfusion pressure (56.55 ± 0.86 vs 68.73 ± 0.69 mmHg in vehicle-treated rats) and an increase in systolic pressure (11, 40 ± 0.05 vs 9.84 ± 0.15 g in vehicle-treated rats). treated rats), rate of tension increase (+ DT / DT; 184.30 ± 0.50 vs 155.20 ± 1.97 g / s in vehicle-treated rats), rate of tension drop (-DT / DT; 179.60 ± 1.39 vs 150.80 ± 2.42 g / s in vehicle-treated rats). A slight increase in heart rate (HR) is also observed (220.40 ± 0.71 vs 214.20 ± 0.74 beats/min in vehicle-treated rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular weight

580.72

Formula

C₂₉H₃₂N₄O₅S₂

CAS No.

304462-19-9

Smiles

O = S (C1 = C (C2 = CC = C (CN3C (C = O) = C (OC) N = C3 C4 = CC = CC = C4) C = C2) C = C (CC (C) C) S1 ) (NC (NCC) = O) = O

Transport

Ambient Temperature in Continental US; may vary elsewhere.

Storage

Dust -20 ° C 3 years
4 ° C 2 years

Insolvent -80 ° C 6 months
-20 ° C 1 month

Leave a Reply

Your email address will not be published. Required fields are marked *

Blog PCR

Human monkeypox – After 40 years, an unintended consequence of smallpox eradication

Smallpox eradication, coordinated by the WHO and certified 40 years ago, led to the cessation of routine smallpox vaccination in most countries. It is estimated that over 70% of the world’s population is no longer protected against smallpox, and through cross-immunity, to closely related orthopox viruses such as monkeypox. Monkeypox is now a re-emerging disease. […]

Read More
Blog parg antibody

A Tale of Two Viruses: Coinfections of Monkeypox and Varicella Zoster Virus in the Democratic Republic of Congo

Recent enhanced monkeypox (MPX) surveillance in the Democratic Republic of Congo, where MPX is endemic, has uncovered multiple cases of MPX and varicella zoster virus (VZV) coinfections. The purpose of this study was to verify if coinfections occur and to characterize the clinical nature of these cases. Clinical, epidemiological, and laboratory results were used to […]

Read More